Core Viewpoint - During the "14th Five-Year Plan" period, Weihai's medical insurance department focuses on enhancing public health and satisfaction through continuous reform and development of the medical insurance system [1] Fund Operation - The medical insurance fund in Weihai operates smoothly, with both employee and resident insurance funds remaining within a sustainable range. A total of 94.69 million yuan has been recovered or refused for payment due to fund supervision [1] - The reimbursement rates for inpatient care are stable at over 80% for employees and over 65% for residents, with a 70% reimbursement rate for eligible key assistance recipients [1] Benefit Guarantee Mechanism - The outpatient mutual guarantee mechanism has been fully established, with 11.69 million outpatient reimbursements amounting to 1.098 billion yuan. The major medical insurance has a maximum reimbursement rate of 90% and a cap of 900,000 yuan, with a total payout of 609 million yuan [1] - The long-term care insurance has been expanded to cover all employees, with a total of 130 million yuan disbursed over five years [1] - The support for maternity benefits has increased, with 917 million yuan reimbursed for various maternity benefits over five years [1] Collaborative Development and Governance - The "Three Medicals" (medical care, medical insurance, and pharmaceuticals) are being integrated to enhance the efficiency of healthcare services. A total of 890 types of drugs and 40 categories of medical consumables have been procured through centralized purchasing, significantly reducing costs [2] - The average price of cochlear implants has dropped from 186,000 yuan to 59,000 yuan, a decrease of 68% [2] Payment Mechanism - The medical insurance payment mechanism is being refined to improve service quality and fund efficiency. The implementation of the DRG payment system has led to a 16% reduction in average hospitalization costs compared to the end of the "13th Five-Year Plan" [4] - The number of drugs covered by the medical insurance has increased from 2,709 to 3,159, with 600 types of negotiated drugs included in the reimbursement list [4] Fund Supervision - The Weihai medical insurance bureau has enhanced its regulatory capabilities through information technology, maintaining a strict stance against fraud. Over five years, 4,513 cases of non-compliance were identified, involving 89.47 million yuan in medical expenses [5] - A total of 307 problem clues were sent to relevant departments, and 2.583 million yuan was voluntarily returned by medical institutions [5] Service System - The service system has been digitized and made more convenient, with 144 hospitals and 1,552 pharmacies capable of cross-province medical settlement. The "We You Bao" insurance allows for direct settlement without claims [6] - The implementation of the electronic medical insurance certificate has been widespread, with over 2.48 million people activating their certificates [6] Future Outlook - The Weihai medical insurance bureau aims to continue focusing on public health and reform during the "15th Five-Year Plan" period, enhancing the medical insurance system and services to contribute to the construction of a "delicate city and happy Weihai" [7]

Core Viewpoint - During the "14th Five-Year Plan" period, Weihai's medical insurance department has focused on enhancing public health and satisfaction through continuous reforms and improvements in medical insurance services [3][10]. Group 1: Fund Operation and Security - The medical insurance fund in Weihai has been operating smoothly, with both employee and resident insurance funds remaining within a sustainable range [3]. - A total of 94.69 million yuan has been recovered or denied in fund supervision efforts [3]. Group 2: Benefit Guarantee Mechanism - The outpatient mutual insurance guarantee mechanism has been fully established, with reimbursement rates for inpatient care at over 80% for employees and 65% for residents [3]. - Outpatient reimbursements have reached 11.69 million instances, totaling 1.098 billion yuan [4]. - The major illness insurance system has been enhanced, with a maximum reimbursement rate of 90% and a cap of 900,000 yuan, totaling 609 million yuan paid out [4]. Group 3: Collaborative Development and Governance - The integration of medical, insurance, and pharmaceutical sectors has been emphasized, with 890 types of drugs and 40 categories of medical supplies included in centralized procurement [5]. - The price of diabetes medication has dropped by 88%, from 600 yuan to 75 yuan per box, and the average price of cochlear implants has decreased by 68% [5]. Group 4: Payment Mechanism - The implementation of the DRG payment system has led to a 16% reduction in average hospitalization costs compared to the end of the "13th Five-Year Plan" [6]. - The number of drugs in the medical insurance directory has increased from 2,709 to 3,159, with 600 types of negotiated drugs now included [6]. Group 5: Fund Supervision - The Weihai medical insurance bureau has maintained a high-pressure stance against fraud, recovering 25.83 million yuan through self-inspection and proactive measures [8]. - A total of 4,513 cases of non-compliance with medical insurance reimbursement have been identified, involving 89.47 million yuan in medical expenses [8]. Group 6: Service System - The establishment of a "15-minute medical insurance service circle" has been achieved, with 858 service stations handling over 100,000 transactions annually [9]. - The "Weihai Medical Insurance" app has facilitated online services for 1.34 million users, with over 85% of medical institutions adopting electronic insurance certificates [9].

Core Points - The National Healthcare Security Administration (NHSA) has published the preliminary results of the review for the 2025 National Basic Medical Insurance (BMI) and commercial insurance innovative drug directories, with 534 drug names approved for the BMI directory and 121 for the commercial insurance directory [1][2] - The review process includes initial review, public announcement of results, re-evaluation, and final announcement, with the initial review being the first step in the overall directory adjustment process [1][2] Summary by Sections Initial Review Results - A total of 718 submissions were received for the BMI directory, involving 633 drug names, with 534 passing the initial review [2] - The number of drugs passing the initial review from outside the directory increased significantly from 249 in 2024 to 310 in 2025 [2] - The approved drugs cover various fields, including oncology, chronic diseases, and rare diseases, with notable CAR-T products and antibody-drug conjugates (ADCs) included [2][3] Pricing and Evaluation - Some high-priced drugs, such as CAR-T therapies and enzyme replacement therapies, have passed the initial review but may not meet the BMI's implicit pricing thresholds [3] - The NHSA emphasizes that passing the initial review does not guarantee inclusion in the BMI directory, as further evaluations and negotiations are required [3][4] Payment Mechanisms and Sustainability - The need for differentiated payment mechanisms to support innovative drugs while ensuring sustainable development is highlighted [4][5] - The introduction of the commercial insurance innovative drug directory aims to enhance service attributes and drive transformation in the commercial insurance sector [5][6] Dual Directory System - The commercial insurance directory received 141 submissions, with 121 drug names passing the initial review, indicating a strong focus on innovative and high-value drugs [5][6] - The dual directory system is expected to foster innovation in drug development and improve patient access to treatments [7]